Written informed consent
Adult patients (older than 18 years of age), male and female, with chronic non-cancer and cancer pain (at least 3 months in duration)
Patients experiencing an average weekly pain intensity score greater than 4 on a 11 points NRS
Subject agreed to follow the protocol
Naïve cannabis patients with chronic non-cancer and cancer pain (not used cannabis in any presentation in the last 12 weeks)
Patients receiving opioids and other concomitant pain medications should have a stable dose for the last 15 days.
Normal cognitive status according to MiniCog
Normal liver function (defined as aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L)
Normal renal function (defined as serum creatinine level <133 µmol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60)
Negative result on ßhuman chorionic gonadotropin pregnancy test (if applicable)
Ability to read and respond to questions in French or English.
A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.

NCT03337503_inc_T2
Person
Adult
NCT03337503_inc_T3
Value
older than 18 years
NCT03337503_inc_T4
Person
age
NCT03337503_inc_T5
Person
male
NCT03337503_inc_T6
Person
female
NCT03337503_inc_T7
Scope
older than 18 years of age
NCT03337503_inc_T8
Qualifier
chronic
NCT03337503_inc_T9
Qualifier
non-cancer
NCT03337503_inc_T10
Qualifier
cancer
NCT03337503_inc_T11
Condition
pain
NCT03337503_inc_T12
Scope
non-cancer and cancer
NCT03337503_inc_T13
Multiplier
at least 3 months in duration
NCT03337503_inc_T14
Measurement
erage weekly pain intensity score g  a 11 points NRS

NCT03337503_inc_T15
Value
greater than 4
NCT03337503_inc_T17
Qualifier
chronic
NCT03337503_inc_T18
Qualifier
non-cancer
NCT03337503_inc_T19
Qualifier
cancer
NCT03337503_inc_T20
Condition
pain
NCT03337503_inc_T21
Scope
non-cancer and cancer
NCT03337503_inc_T22
Measurement
not
NCT03337503_inc_T23
Drug
cannabis
NCT03337503_inc_T24
Temporal
in the last 12 weeks
NCT03337503_inc_T25
Condition
Naïve cannabis
NCT03337503_inc_T26
Scope
not used cannabis in any presentation in the last 12 weeks
NCT03337503_inc_T27
Drug
opioids
NCT03337503_inc_T28
Drug
pain medications
NCT03337503_inc_T29
Qualifier
other
NCT03337503_inc_T30
Qualifier
stable dose
NCT03337503_inc_T31
Temporal
for the last 15 days
NCT03337503_inc_T32
Scope
opioids and other concomitant pain medications
NCT03337503_inc_T33
Procedure
MiniCog
NCT03337503_inc_T34
Condition
Normal cognitive status
NCT03337503_inc_T35
Condition
Normal liver function
NCT03337503_inc_T36
Measurement
aspartate aminotransferase
NCT03337503_inc_T37
Value
10-40 U/L
NCT03337503_inc_T38
Measurement
alanine aminotransferase
NCT03337503_inc_T39
Value
7-56 U/L
NCT03337503_inc_T40
Scope
aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L
NCT03337503_inc_T41
Condition
Normal renal function
NCT03337503_inc_T42
Measurement
serum creatinine level
NCT03337503_inc_T43
Value
<133 µmol/L
NCT03337503_inc_T44
Measurement
Estimated Glomerular Filtration Rate (eGFR)
NCT03337503_inc_T45
Value
greater than or equal to 60
NCT03337503_inc_T46
Scope
serum creatinine level <133 µmol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60
NCT03337503_inc_T47
Value
Negative
NCT03337503_inc_T48
Measurement
ßhuman chorionic gonadotropin pregnancy test